Abstract
Cell adhesion molecules (CAMs) are transmembrane proteins that mediate adhesion and interactions between cells or cell and extra-cellular matrix. Increased expression and activation of CAMs in vascular endothelial cells and circulating leukocytes, as occurring in the settings of inflammation, hypercholesterolemia, hypertension and diabetes, stimulates leukocyte recruitment into the vascular endothelium, an important step in the pathogenesis of atherosclerosis. CAMs are a potential therapeutic target in clinical practice and in recent years pharmaceutical agents with specific effects on the production and function of these molecules have been studied and developed. This article reviews recent progress regarding pathophysiology of CAMs in atherogenesis and pharmaceutical products or chemicals that are active against CAMs, and assesses the possibilities for clinical developments in this area that might enhance the prevention, monitoring and treatment of atherosclerotic cardiovascular diseases.
Keywords: Atherosclerosis, cell adhesion molecules, leukocyte recruitment, vascular endothelium, pharmaceutical therapy, glycoproteins, in vitro, aortic, leukocytes, transmembrane
Mini-Reviews in Medicinal Chemistry
Title: Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Volume: 12 Issue: 2
Author(s): S. Ling, L. Nheu and P. A. Komesaroff
Affiliation:
Keywords: Atherosclerosis, cell adhesion molecules, leukocyte recruitment, vascular endothelium, pharmaceutical therapy, glycoproteins, in vitro, aortic, leukocytes, transmembrane
Abstract: Cell adhesion molecules (CAMs) are transmembrane proteins that mediate adhesion and interactions between cells or cell and extra-cellular matrix. Increased expression and activation of CAMs in vascular endothelial cells and circulating leukocytes, as occurring in the settings of inflammation, hypercholesterolemia, hypertension and diabetes, stimulates leukocyte recruitment into the vascular endothelium, an important step in the pathogenesis of atherosclerosis. CAMs are a potential therapeutic target in clinical practice and in recent years pharmaceutical agents with specific effects on the production and function of these molecules have been studied and developed. This article reviews recent progress regarding pathophysiology of CAMs in atherogenesis and pharmaceutical products or chemicals that are active against CAMs, and assesses the possibilities for clinical developments in this area that might enhance the prevention, monitoring and treatment of atherosclerotic cardiovascular diseases.
Export Options
About this article
Cite this article as:
Ling S., Nheu L. and A. Komesaroff P., Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis, Mini-Reviews in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/138955712798995057
DOI https://dx.doi.org/10.2174/138955712798995057 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances
Current Hypertension Reviews Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity
Current Vascular Pharmacology Acknowledgement To Reviewers
Current Hypertension Reviews Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Capsule Endoscopy in Crohn’s Disease
Current Drug Targets Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Calcium Pattern Assessment in Patients with Severe Aortic Stenosis Via the Chou’s 5-Steps Rule
Current Pharmaceutical Design Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Diversity in Hypertension and Cardiovascular Disease Around the Globe
Current Hypertension Reviews COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Conformational Engineering of Lipases via Directed Immobilisation: Improving the Resolution of Chiral Drugs
Medicinal Chemistry Reviews - Online (Discontinued) The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery